Tremoulet Adriana H, Albani Salvatore
University of California, Department of Pediatrics, 9500 Gilman Drive, MC 0731, La Jolla, CA 92093, USA.
Expert Opin Investig Drugs. 2006 Nov;15(11):1427-41. doi: 10.1517/13543784.15.11.1427.
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease that causes significant morbidity and mortality. The pathogenesis outlined to date in RA consists of a cascade of pro-inflammatory cytokines and chemokines leading to the recruitment of inflammatory cells and the self perpetuation of inflammation, ultimately leading to cartilage and bone destruction. The dramatic progress in understanding the molecular immunology in RA has led to a transition from conventional treatment with aggressive immune suppression to targeted biological-based therapies that control the inflammatory pathways associated with RA. This article reviews the current biological and small-molecule therapies approved for the treatment of RA and those in development, including antibodies, tolerising agents and vaccines.
类风湿性关节炎(RA)是一种慢性全身性炎症性疾病,可导致严重的发病率和死亡率。迄今为止,RA的发病机制包括一系列促炎细胞因子和趋化因子,导致炎症细胞的募集和炎症的自我持续,最终导致软骨和骨破坏。在理解RA分子免疫学方面取得的巨大进展,已促使治疗从采用积极免疫抑制的传统疗法,转变为控制与RA相关炎症途径的靶向生物疗法。本文综述了目前已批准用于治疗RA的生物和小分子疗法以及正在研发的疗法,包括抗体、免疫耐受剂和疫苗。